{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:18:13Z","timestamp":1787728693775,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Project of Changzhou Science and Technology","award":["CJ20220220"],"award-info":[{"award-number":["CJ20220220"]}]},{"name":"the Geriatric Project of Jiangsu Health Commission","award":["LKM2023036"],"award-info":[{"award-number":["LKM2023036"]}]},{"name":"the Project of Changzhou Health Commission","award":["ZD202324 and CZQM2023020"],"award-info":[{"award-number":["ZD202324 and CZQM2023020"]}]},{"name":"the Research Foundation of Jiangsu Province Administration of Traditional Chinese Medicine","award":["MS2023088"],"award-info":[{"award-number":["MS2023088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and aim<\/jats:title>\n            <jats:p>Nonalcoholic fatty liver disease (NAFLD) with liver fibrosis is associated with liver-related mortality and cardiovascular disease. Estimated glucose disposal rate (eGDR), which is an insulin resistance\u2013related index, is related to the mortality caused by NAFLD. This study aimed to investigate the predictive value of eGDR for liver fibrosis in patients with NAFLD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The data from the National Health and Nutrition Examination Survey 2017\u20132020.03 were analyzed in the present study. NAFLD was diagnosed using the controlled attenuation parameter (CAP) tests using FibroScan<jats:sup>\u00ae<\/jats:sup> model 502 V2 Touch.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The data from 1585 individuals were analyzed, including 224 with significant fibrosis and 1361 with nonsignificant fibrosis. Individuals with significant fibrosis were older and had higher CAP values and lower eGDRs (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). A negative correlation was found between eGDR and stiffness degrees (odds ratio: 0.643, 95% confidence interval: 0.643\u20130.726, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); the correlation was also significant after adjusting for age, sex, and ethics (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). For participants with obesity and overweight, eGDR was negatively correlated with age, CAP, body mass index (BMI), waist circumference, C-reactive protein level, and white blood cell (WBC) count (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The multivariate analysis revealed that age, eGDR, BMI, aspartate aminotransferase (AST), and WBC and platelet (PLT) counts (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) were independent risk factors for significant fibrosis. A model incorporating eGDR, BMI, age, AST, WBC, and PLT had an AUROC of 0.822, and was superior to conventional noninvasive scoring systems, including the AST-to-PLT ratio index, fibrosis-4 level, and gamma-glutamyl transpeptidase to platelet ratio for individuals with obesity (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Low eGDR was negatively correlated with liver fibrosis in individuals with NAFLD and obesity, and a model incorporating eGDR, BMI, age, AST, WBC, and PLT demonstrated strong predictive value for fibrosis evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12876-025-03798-y","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:08:27Z","timestamp":1743300507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A negative correlation of low estimated glucose disposal rate with significant liver fibrosis in adults with NAFLD and obesity: results from NHANES 2017\u20132020"],"prefix":"10.1186","volume":"25","author":[{"given":"Xue-Cheng","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"10","key":"3798_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstrom","year":"2024","unstructured":"Hagstrom H, Shang Y, Hegmar H,Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944\u201356. https:\/\/doi.org\/10.1016\/S2468-1253(24)00193-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3798_CR2","doi-asserted-by":"publisher","unstructured":"Kim KSHS, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384e076388. https:\/\/doi.org\/10.1136\/bmj-2023-076388.","DOI":"10.1136\/bmj-2023-076388"},{"issue":"9","key":"3798_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH,Underwood FE,King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3798_CR4","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N,Norouzi N, Joukar F,Habibi A, Javid M, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review Meta-Analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55(6):103043. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103043.","journal-title":"Arch Med Res"},{"key":"3798_CR5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae619","author":"G Georgiopoulos","year":"2024","unstructured":"Georgiopoulos G, Athanasopoulos S, Mavraganis G, Konstantaki C,Papaioannou M, Delialis D, et al. Incremental value of blood-based markers of liver fibrosis in cardiovascular risk stratification. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/clinem\/dgae619.","journal-title":"J Clin Endocrinol Metab"},{"key":"3798_CR6","doi-asserted-by":"publisher","unstructured":"Alkaabi J, Afandi B, Alhaj O,Kanwal D,Agha A. Identifying metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus using clinic-based prediction tools. Front Med (Lausanne). 2024:111425145. https:\/\/doi.org\/10.3389\/fmed.2024.1425145.","DOI":"10.3389\/fmed.2024.1425145"},{"key":"3798_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rgmxen.2024.09.002","author":"BA Priego-Parra","year":"2024","unstructured":"Priego-Parra BA, Triana-Romero A, Bernal-Reyes R, Icaza-Chavez ME, Martinez-Vazquez SE, Amieva-Balmori M, et al. Comparative evaluation of APRI, FIB-4, HFS, and NFS: scoring tools for liver fibrosis in a Mexican population with MASLD. Rev Gastroenterol Mex (Engl Ed). 2024. https:\/\/doi.org\/10.1016\/j.rgmxen.2024.09.002.","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"3798_CR8","doi-asserted-by":"publisher","unstructured":"Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024:1223\u201310. https:\/\/doi.org\/10.1016\/j.ejim.2023.11.005.","DOI":"10.1016\/j.ejim.2023.11.005"},{"issue":"1","key":"3798_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-023-04007-8","volume":"21","author":"L Wang","year":"2023","unstructured":"Wang L, Yi J, Guo J, Ren X. Weigh change across adulthood is related to the presence of NAFLD: results from NHANES III. J Transl Med. 2023;21(1):142. https:\/\/doi.org\/10.1186\/s12967-023-04007-8.","journal-title":"J Transl Med"},{"issue":"1","key":"3798_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12889-025-21943-w","volume":"25","author":"Q He","year":"2025","unstructured":"He Q, Liu X,Ding G, Wang Y, Luo X,Cao W,Xing W. The relationship between serum uric acid level and non-alcoholic fatty liver disease in Northern China: a retrospective cohort study. BMC Public Health. 2025;25(1):718. https:\/\/doi.org\/10.1186\/s12889-025-21943-w.","journal-title":"BMC Public Health"},{"key":"3798_CR11","doi-asserted-by":"publisher","unstructured":"Lajeunesse-Trempe F, Dugas S, Maltais-Payette I, Tremblay EJ, Piche ME, G, KD, et al. Anthropometric indices and metabolic Dysfunction-Associated fatty liver disease in males and females living with severe obesity. Can J Gastroenterol Hepatol. 2025:20255545227. https:\/\/doi.org\/10.1155\/cjgh\/5545227.","DOI":"10.1155\/cjgh\/5545227"},{"key":"3798_CR12","doi-asserted-by":"publisher","unstructured":"de Vries M, Westerink J, El-Morabit F, Kaasjager H, de Valk HW. Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. Diabetes Res Clin Pract. 2022:186109827. https:\/\/doi.org\/10.1016\/j.diabres.2022.109827.","DOI":"10.1016\/j.diabres.2022.109827"},{"issue":"7","key":"3798_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/met.2015.0018","volume":"13","author":"CN Ercin","year":"2015","unstructured":"Ercin CN, Dogru T, Genc H, Aslan F, Gurel H, et al. Insulin resistance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2015;13(7):319\u201325. https:\/\/doi.org\/10.1089\/met.2015.0018.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"3798_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12933-024-02354-4","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang F, Chen Y. Association of triglyceride glucose-related parameters with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999\u20132018. Cardiovasc Diabetol. 2024;23(1):262. https:\/\/doi.org\/10.1186\/s12933-024-02354-4.","journal-title":"Cardiovasc Diabetol"},{"key":"3798_CR15","doi-asserted-by":"publisher","unstructured":"Song J, Ma R, Yin L. Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2024:151398265. https:\/\/doi.org\/10.3389\/fendo.2024.1398265.","DOI":"10.3389\/fendo.2024.1398265"},{"issue":"4","key":"3798_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/met.2023.0217","volume":"22","author":"MM Canat","year":"2024","unstructured":"Canat MM, Altuntas Y. Comparison of two estimated glucose disposal rate methods for detecting insulin resistance in adults with type 1 diabetes mellitus. Metab Syndr Relat Disord. 2024;22(4):295\u2013301. https:\/\/doi.org\/10.1089\/met.2023.0217.","journal-title":"Metab Syndr Relat Disord"},{"issue":"4","key":"3798_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jand.2018.05.007","volume":"119","author":"PA Tuma","year":"2019","unstructured":"Tuma PA. Dietary guidelines 2020\u20132025: update on academy efforts. J Acad Nutr Diet. 2019;119(4):672\u20134. https:\/\/doi.org\/10.1016\/j.jand.2018.05.007.","journal-title":"J Acad Nutr Diet"},{"key":"3798_CR18","doi-asserted-by":"publisher","unstructured":"Cai J, Chen D, Luo W,Xu F, Feng X, Zhang L, et al. The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017\u20132020. Front Nutr. 2024:111366843. https:\/\/doi.org\/10.3389\/fnut.2024.1366843.","DOI":"10.3389\/fnut.2024.1366843"},{"issue":"5","key":"3798_CR19","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF,Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"1","key":"3798_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12944-024-02027-x","volume":"23","author":"WF Xi","year":"2024","unstructured":"Xi WF, Yang AM. Association between cardiometabolic index and controlled Attenuation parameter in U.S. Adults with NAFLD: findings from NHANES (2017\u20132020). Lipids Health Dis. 2024;23(1):40. https:\/\/doi.org\/10.1186\/s12944-024-02027-x.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"3798_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","volume":"81","author":"L Castera","year":"2024","unstructured":"Castera L, Garteiser P, Laouenan C, Vidal-Trecan T, Vallet-Pichard A, Manchon P, et al. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol. 2024;81(2):195\u2013206. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.023.","journal-title":"J Hepatol"},{"issue":"16","key":"3798_CR22","doi-asserted-by":"publisher","first-page":"e3372","DOI":"10.1097\/md.0000000000003372","volume":"95","author":"QSJHY Li","year":"2016","unstructured":"Li QSJHY, Li XZQ, Li W, et al. The Gamma-Glutamyl-Transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: A retrospective cohort study in China. Med (Baltim). 2016;95(16):e3372. https:\/\/doi.org\/10.1097\/md.0000000000003372.","journal-title":"Med (Baltim)"},{"issue":"1","key":"3798_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s40001-024-02065-2","volume":"29","author":"G Xia","year":"2024","unstructured":"Xia G, Xu Y, Zhang C,Li M, Li H, Chen C. High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver disease in non-obese people: a cross-sectional study. Eur J Med Res. 2024;29(1):496. https:\/\/doi.org\/10.1186\/s40001-024-02065-2.","journal-title":"Eur J Med Res"},{"issue":"1","key":"3798_CR24","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","volume":"11","author":"G Lee","year":"2020","unstructured":"Lee G, You HJ,Bajaj JS,Joo SK,Yu J, Park S, et al. Distinct signatures of gut Microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020;11(1):4982. https:\/\/doi.org\/10.1038\/s41467-020-18754-5.","journal-title":"Nat Commun"},{"key":"3798_CR25","doi-asserted-by":"publisher","unstructured":"Mahapatro A, Bawna F, Kumar V, Daryagasht AA,Gupta S, Raghuma N, et al. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: an umbrella study on meta-analyses. Clin Nutr ESPEN. 2023:57475\u2013486. https:\/\/doi.org\/10.1016\/j.clnesp.2023.07.087.","DOI":"10.1016\/j.clnesp.2023.07.087"},{"issue":"10","key":"3798_CR26","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","volume":"38","author":"L Rong","year":"2023","unstructured":"Rong L, Ch\u2019ng D,Jia P, Tsoi KKF,Wong SH,Sung JJY. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2023;38(10):1682\u201394. https:\/\/doi.org\/10.1111\/jgh.16256.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"3798_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41387-024-00281-7","volume":"14","author":"A Vakilpour","year":"2024","unstructured":"Vakilpour A, Amini-Salehi E, Soltani Moghadam A, Keivanlou MH,Letafatkar N, Habibi A, et al. The effects of gut Microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review. Nutr Diabetes. 2024;14(1):25. https:\/\/doi.org\/10.1038\/s41387-024-00281-7.","journal-title":"Nutr Diabetes"},{"issue":"1","key":"3798_CR28","doi-asserted-by":"publisher","first-page":"e180124225761","DOI":"10.2174\/0115733998284844240102110559","volume":"21","author":"MH Keivanlou","year":"2024","unstructured":"Keivanlou MH, Amini-Salehi E, Hassanipour S, Zare R, Mohammadi-Vajari E, Hashemi M, et al. The value of Microbiome-targeted therapy on lipid indices of patients with type 2 diabetes mellitus: an umbrella Meta-analysis of randomized controlled trials. Curr Diabetes Rev. 2024;21(1):e180124225761. https:\/\/doi.org\/10.2174\/0115733998284844240102110559.","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"3798_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","volume":"17","author":"European Association for the Study of the L,European Association for the Study of D,European Association for the Study of O","year":"2024","unstructured":"European Association for the Study of the L,European Association for the Study of D,European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines on the management of metabolic Dysfunction-Associated steatotic liver disease (MASLD). Obes Facts. 2024;17(4):374\u2013444. https:\/\/doi.org\/10.1159\/000539371.","journal-title":"Obes Facts"},{"key":"3798_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s40477-024-00971-z","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Kumari A, Murty RS. FibroScan\u2019s evolution: a critical 20-year review. J Ultrasound. 2024. https:\/\/doi.org\/10.1007\/s40477-024-00971-z.","journal-title":"J Ultrasound"},{"issue":"1","key":"3798_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12889-025-21322-5","volume":"25","author":"H Peng","year":"2025","unstructured":"Peng H, Zhao Z,Gong J, He K. BMI trajectories are associated with NAFLD and advanced fibrosis via aging-inflammation mediation. BMC Public Health. 2025;25(1):147. https:\/\/doi.org\/10.1186\/s12889-025-21322-5.","journal-title":"BMC Public Health"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03798-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:08:35Z","timestamp":1743300515000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03798-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03798-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey protocol was approved by the National Center for Health Statistics Ethics Review Committee and the database was publicly available. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}